Related Experiment Videos
Increased B-type natriuretic peptide (BNP) level is a strong predictor for cardiac dysfunction in intensive care unit
1Intensive Care Unit, Nepean Hospital, University of Sydney, PO Box 63, Penrith, N.S.W. 2750.
Insights
B-type natriuretic peptide (BNP) effectively screens for cardiac dysfunction in Intensive Care Unit (ICU) patients. A BNP level below 144 pg/ml accurately identifies patients without significant cardiac issues, enabling timely interventions.
Area of Science:
- Cardiology
- Critical Care Medicine
Background:
- Patients in Intensive Care Units (ICUs) often have cardiac dysfunction.
- Diagnostic uncertainty can delay crucial early interventions for cardiac failure.
Purpose of the Study:
- To evaluate B-type natriuretic peptide (BNP) as a screening tool for cardiac dysfunction in ICU admissions.
- To determine the efficacy of BNP in identifying patients requiring cardiac investigation.
Main Methods:
- A prospective study included all patients admitted to a combined medical/surgical ICU over four weeks.
- B-type natriuretic peptide (BNP) was measured upon admission using a point-of-care device.
- Clinicians were blinded to BNP results during initial diagnosis of cardiac dysfunction.
Main Results:
- Patients with cardiac dysfunction showed significantly higher BNP levels (516 pg/ml) compared to those without (67 pg/ml).
- A BNP cut-off of 144 pg/ml demonstrated 92% sensitivity and 86% specificity for cardiac dysfunction.
- The negative predictive value for cardiac dysfunction was 96% at this cut-off.
Conclusions:
- BNP is a rapid, affordable, and reliable screening tool for cardiac dysfunction in the ICU.
- Elevated BNP levels warrant further cardiac evaluation for prompt management of decompensation.
- BNP testing facilitates early intervention strategies in critically ill patients with cardiac issues.
Abstract:
Patients admitted to an Intensive Care Unit (ICU) frequently have underlying cardiac dysfunction. Early interventions are sometimes difficult to initiate because of diagnostic uncertainty as to whether cardiac failure is present As B-type natriuretic peptide (BNP) has been shown to be increased in cardiac dysfunction, we sought to demonstrate whether BNP can be used as a screening tool for cardiac dysfunction in patients admitted to ICU. All patients admitted to a combined medical and surgical ICU over a four-week period were included in the study. BNP was measured on the point of admission using a hand-held meter. Clinicians were blinded from the measurement when diagnoses were made as to whether or not the patients had clinically significant cardiac dysfunction. Patients with cardiac dysfunction had a significantly higher level of BNP when compared to the non-cardiac dysfunction group: 516 +/- 385 pg/ml (n = 26) v 67 +/- 89 pg/ml (n = 58) (P < 0.0001) A BNP cut-off value at 144 pg/ml exhibited a 92% sensitivity, 86% specificity and 96% negative predictive value. The sensitivity improved to 96% when the analysis was confined to patients > or = 55 years. At this cut-off value, BNP is a strong predictor of cardiac dysfunction. BNP measurement offers a rapid and affordable way to screen for cardiac dysfunction in patients admitted to ICU. An increased BNP level warrants further cardiac investigations so as to implement early interventions for cardiac decompensation in ICU patients.